| The Simcyp® Population-based ADME Simulator M Jamei, S Marciniak, K Feng, A Barnett, G Tucker, A Rostami-Hodjegan Expert opinion on drug metabolism & toxicology 5 (2), 211-223, 2009 | 599 | 2009 |
| Population-based mechanistic prediction of oral drug absorption M Jamei, D Turner, J Yang, S Neuhoff, S Polak, A Rostami-Hodjegan, ... The AAPS journal 11, 225-237, 2009 | 536 | 2009 |
| A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology … M Jamei, GL Dickinson, A Rostami-Hodjegan Drug metabolism and pharmacokinetics 24 (1), 53-75, 2009 | 409 | 2009 |
| Prediction of intestinal first-pass drug metabolism J Yang, M Jamei, KR Yeo, GT Tucker, A Rostami-Hodjegan Current drug metabolism 8 (7), 676-684, 2007 | 396 | 2007 |
| PBPK models for the prediction of in vivo performance of oral dosage forms ES Kostewicz, L Aarons, M Bergstrand, MB Bolger, A Galetin, O Hatley, ... European Journal of Pharmaceutical Sciences 57, 300-321, 2014 | 347 | 2014 |
| Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective M Shebley, P Sandhu, A Emami Riedmaier, M Jamei, R Narayanan, ... Clinical Pharmacology & Therapeutics 104 (1), 88-110, 2018 | 337 | 2018 |
| Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions J Yang, M Liao, M Shou, M Jamei, KR Yeo, GT Tucker, ... Current drug metabolism 9 (5), 384-393, 2008 | 265 | 2008 |
| Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance M Jamei Current pharmacology reports 2 (3), 161-169, 2016 | 254 | 2016 |
| ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport‐mediated PK and DDIs in humans MJ Zamek‐Gliszczynski, CA Lee, A Poirier, J Bentz, X Chu, H Ellens, ... Clinical Pharmacology & Therapeutics 94 (1), 64-79, 2013 | 222 | 2013 |
| Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption … A S. Darwich, S Neuhoff, M Jamei, A Rostami-Hodjegan Current drug metabolism 11 (9), 716-729, 2010 | 214 | 2010 |
| Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound … KR Yeo, M Jamei, J Yang, GT Tucker, A Rostami-Hodjegan European Journal of Pharmaceutical Sciences 39 (5), 298-309, 2010 | 214 | 2010 |
| PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals FY Bois, M Jamei, HJ Clewell Toxicology 278 (3), 256-267, 2010 | 213 | 2010 |
| Misuse of the well-stirred model of hepatic drug clearance J Yang, M Jamei, KR Yeo, A Rostami-Hodjegan, GT Tucker Drug Metabolism and Disposition 35 (3), 501-502, 2007 | 200 | 2007 |
| A mechanistic framework for in vitro–in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and cyclosporine M Jamei, F Bajot, S Neuhoff, Z Barter, J Yang, A Rostami-Hodjegan, ... Clinical pharmacokinetics 53, 73-87, 2014 | 191 | 2014 |
| Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment … J Bentz, MP O’Connor, D Bednarczyk, JA Coleman, C Lee, J Palm, ... Drug metabolism and disposition 41 (7), 1347-1366, 2013 | 184 | 2013 |
| Modeling and predicting drug pharmacokinetics in patients with renal impairment K Rowland Yeo, M Aarabi, M Jamei, A Rostami-Hodjegan Expert review of clinical pharmacology 4 (2), 261-274, 2011 | 175 | 2011 |
| Does age affect gastric emptying time? A model‐based meta‐analysis of data from premature neonates through to adults JJ Bonner, P Vajjah, K Abduljalil, M Jamei, A Rostami‐Hodjegan, ... Biopharmaceutics & drug disposition 36 (4), 245-257, 2015 | 158 | 2015 |
| A pregnancy physiologically based pharmacokinetic (p‐PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4 L Gaohua, K Abduljalil, M Jamei, TN Johnson, A Rostami‐Hodjegan British journal of clinical pharmacology 74 (5), 873-885, 2012 | 139 | 2012 |
| The simcyp population based simulator: architecture, implementation, and quality assurance M Jamei, S Marciniak, D Edwards, K Wragg, K Feng, A Barnett, ... In Silico Pharmacology 1, 1-14, 2013 | 134 | 2013 |
| Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover KR Yeo, RL Walsky, M Jamei, A Rostami-Hodjegan, GT Tucker European Journal of Pharmaceutical Sciences 43 (3), 160-173, 2011 | 127 | 2011 |
Amin Rostami-HodjeganProfessor of Systems Pharmacology, University of Manchester, UKEmail được xác minh tại manchester.ac.uk